Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63

Molecular Cancer Therapeutics

Volumn 15, Issue 11, 2016, Pages 2688-2697

  De Goeij, Bart E C G ^a   Vink, Tom ^a   Ten Napel, Hendrik ^a   Breij, Esther C W ^a   Satijn, David ^a   Wubbolts, Richard ^b   Miao, David ^c   Parren, Paul W H I ^a,d,e  

^a GENMAB   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Concortis Biosystems Corp ^*  (United States)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BETA1 INTEGRIN; BISPECIFIC ANTIBODY; CD63 ANTIGEN; CYTOTOXIC AGENT; DUOSTATIN 3 EPIDERMAL GROWTH FACTOR RECEPTOR 2 CD63 BISPECIFIC ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G1 ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYSOSOME; LYSOSOME MEMBRANE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; SINGLE DRUG DOSE; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG RELEASE; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIGENS, CD63; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG LIBERATION; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; LYSOSOMES; MICE; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; RECEPTOR, ERBB-2; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995387420     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0364     Document Type: Article

References (36)

1. Burris HA. Developments in the use of antibody-drug conjugates. Am Soc Clin Oncol Educ Book 2013. doi: 10.1200/EdBook-AM.2013.33. e99.
2. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, SchroederGM, Vite GD, et al. Antibody-drug conjugates: Current status and future directions. Drug Discov Today 2014; 19: 869-81.
3. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A 1983; 80: 2258-62.
4. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19: 6102-14.
5. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 1996; 271: 5251-7.
6. Kamiguchi H, Lemmon V. Recycling of the cell adhesion molecule L1 in axonal growth cones. J Neurosci 2000; 20: 3676-86.
7. Pellinen T, Ivaska J. Integrin traffic. J Cell Sci 2006; 119: 3723-31.
8. de Goeij BE, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther 2015; 14: 1130-40.
9. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. ProcNatl Acad SciUS A 2013; 110: 5145-50.
10. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009; 315: 1584-92.
11. Duffield A, Kamsteeg EJ, Brown AN, Pagel P, Caplan MJ. The tetraspanin CD63 enhances the internalization of the H,K-ATPase beta-subunit. Proc Natl Acad Sci U S A 2003; 100: 15560-5.
12. Takino T, Miyamori H, Kawaguchi N, Uekita T, Seiki M, Sato H. Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem Biophys Res Commun 2003; 304: 160-6.
13. Tugues S, Honjo S, Konig C, Padhan N, Kroon J, Gualandi L, et al. Tetraspanin CD63 promotes vascular endothelial growth factor receptor 2-beta1 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo. J Biol Chem 2013; 288: 19060-71.
14. Janvier K, Bonifacino JS. Role of the endocytic machinery in the sorting of lysosome-associated membrane proteins. Mol Biol Cell 2005; 16: 4231-42.
15. Jelovac D, Emens LA. HER2-directed therapy for metastatic breast cancer. Oncology (Williston Park) 2013; 27: 166-75.
16. de Goeij BE, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, et al. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization- mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. MAbs 2014; 6: 392-402.
17. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532: 253-68.
18. Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016; 29: 117-29.
19. Metzelaar MJ, Schuurman HJ, Heijnen HF, Sixma JJ, Nieuwenhuis HK. Biochemical andimmunohistochemical characteristics ofCD62 and CD63 monoclonal antibodies. Expression of GMP-140 and LIMP-CD63 (CD63 antigen) in human lymphoid tissues. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 61: 269-77.
20. Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma JJ, de Jong RN. A simple, robust and highly efficient transient expression system for producing antibodies. Methods 2014; 65: 5-10.
21. Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc 2014; 9: 2450-63.
22. Parren PW, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF3rd, Burton DR, et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995; 9: F1-6.
23. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28: 1203-7.
24. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012; 287: 11090-7.
25. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 2011; 23: 607-14.
26. Arjonen A, Alanko J, Veltel S, Ivaska J. Distinct recycling of active and inactive beta1 integrins. Traffic 2012; 13: 610-25.
27. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21: 778-84.
28. Waldron NN, Barsky SH, Dougherty PR, Vallera DA. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target Oncol 2014; 9: 239-49.
29. OhS, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg 2011; 114: 1662-71.
30. Vallera DA, Oh S, Chen H, Shu Y, Frankel AE. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther 2010; 9: 1872-83.
31. Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, et al. Phase I study of a bispecific ligand-directed toxin targetingCD22and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res 2015; 21: 1267-72.
32. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab- DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-90.
33. Nydegger S, Khurana S, Krementsov DN, Foti M, Thali M. Mapping of tetraspanin-enriched microdomains that can function as gateways for HIV- 1. J Cell Biol 2006; 173: 795-807.
34. Nagy P, Vereb G, Sebestyen Z, Horvath G, Lockett SJ, Damjanovich S, et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- And heteroassociations of ErbB2. J Cell Sci 2002; 115: 4251-62.
35. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci U S A 2003; 100: 5813-8.
36. Gamage DG, Hendrickson TL. GPI transamidase and GPI anchored proteins: Oncogenes and biomarkers for cancer. Crit Rev Biochem Mol Biol 2013; 48: 446-64.